Aegis Capital Reaffirms Adamas Pharma (ADMS) at 'Buy'; Dyskinesia Secondary Endpoint Also Seen as Key
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Adamas Pharma (ADMS) Sees Red-to-Green Move
December 24, 2015 11:28 AM ESTAfter trading down as much as 8% earlier, yesterday's big mover Adamas Pharma (NASDAQ: ADMS) is back in positive territory.
... MoreAdamas Pharmaceuticals (ADMS) PT Raised to $37 at Credit Suisse
December 24, 2015 7:37 AM ESTCredit Suisse analyst V. Divan reiterated an Outperform rating and raised its price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $37.00 (from $35.00) after raising the probability of success for ADS-5102 to 90% (from 80%) on the back of encouraging topline phase 3 data for their lead internal asset... More
Adamas Pharma (ADMS) Ramps Into the Close
December 23, 2015 3:38 PM ESTAdamas Pharma (NASDAQ: ADMS) ramps into the close. Shares are up 73.6% and near the highs after earlier announcing statistically significant ADS-5102 Phase 3 EASE LID data.
... MoreAdamas Pharmaceuticals (ADMS) PT Raised to $38 at Needham & Company
December 23, 2015 2:18 PM ESTNeedham & Company analyst Serge Belanger reiterated a Buy rating and raised his price target on Adamas Pharmaceuticals (NASDAQ: ADMS) to $38.00 (from $33.00) after the company reported positive top-line results from its first ph 3 study evaluating ADS-5102 in the treatment of levodopa-induced dyskinesia (LID) in Parkinson's... More
